{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:28Z","timestamp":1786982668475,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13555-023-01005-y","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:02:03Z","timestamp":1694613723000},"page":"2431-2441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children"],"prefix":"10.1007","volume":"13","author":[{"given":"Marta","family":"Ko\u0142t-Kami\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Osi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kaznowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"issue":"2","key":"1005_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/archderm.100.2.175","volume":"100","author":"CL Davidson Jr","year":"1969","unstructured":"Davidson CL Jr, Winkelmann RK, Kierland RR. Pityriasis rubra pilaris. A follow-up study of 57 patients. Arch Dermatol. 1969;100(2):175\u20138. https:\/\/doi.org\/10.1001\/archderm.100.2.175.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1005_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jdv.14761","volume":"32","author":"S Roenneberg","year":"2018","unstructured":"Roenneberg S, Biedermann T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. J Eur Acad Dermatol Venereol. 2018;32(6):889\u201398. https:\/\/doi.org\/10.1111\/jdv.14761. (Epub 2018 Jan 17).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1005_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2230.1980.tb01676.x","volume":"5","author":"WA Griffiths","year":"1980","unstructured":"Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5(1):105\u201312. https:\/\/doi.org\/10.1111\/j.1365-2230.1980.tb01676.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1005_CR4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2133.1995.tb06939.x","volume":"133","author":"ES Miralles","year":"1995","unstructured":"Miralles ES, N\u00fa\u00f1ez M, De Las Heras ME, P\u00e9rez B, Moreno R, Ledo A. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol. 1995;133(6):990\u20133. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb06939.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1005_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/11530070-000000000-00000","volume":"11","author":"A Klein","year":"2010","unstructured":"Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol. 2010;11(3):157\u201370. https:\/\/doi.org\/10.2165\/11530070-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1005_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","volume":"91","author":"D Fuchs-Telem","year":"2012","unstructured":"Fuchs-Telem D, Sarig O, van Steensel MA, Isakov O, Israeli S, Nousbeck J, Richard K, Winnepenninckx V, Vernooij M, Shomron N, Uitto J, Fleckman P, Richard G, Sprecher E. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91(1):163\u201370. https:\/\/doi.org\/10.1016\/j.ajhg.2012.05.010. (Epub 2012 Jun 14).","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1005_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","volume":"152","author":"NA Ross","year":"2016","unstructured":"Ross NA, Chung HJ, Li Q, Andrews JP, Keller MS, Uitto J. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients. JAMA Dermatol. 2016;152(6):670\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2016.0091.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1005_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaad.2018.03.036","volume":"79","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol. 2018;79(2):353\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.036. (e11; Epub 2018 Mar 30).","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1005_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","volume":"153","author":"L Feldmeyer","year":"2017","unstructured":"Feldmeyer L, Mylonas A, Demaria O, Mennella A, Yawalkar N, Laffitte E, Hohl D, Gilliet M, Conrad C. Interleukin 23-Helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5384.","journal-title":"JAMA Dermatol"},{"key":"1005_CR10","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u2013. Risankizumab. 2021. PMID: 34251778."},{"issue":"6","key":"1005_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723.","journal-title":"JAMA Dermatol"},{"issue":"16","key":"1005_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1607017.","journal-title":"N Engl J Med"},{"issue":"10148","key":"1005_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6. (Epub 2018 Aug 7).","journal-title":"Lancet"},{"issue":"10198","key":"1005_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3. (Epub 2019 Jul 4. Erratum in: Lancet. 2019 Jul 16).","journal-title":"Lancet"},{"issue":"4","key":"1005_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO, Japanese Ixekizumab Study Group. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362. https:\/\/doi.org\/10.1111\/1346-8138.13622. (Epub 2016 Oct 11).","journal-title":"J Dermatol"},{"issue":"3","key":"1005_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.064.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1005_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466\u201375. https:\/\/doi.org\/10.1111\/bjd.20818. (Epub 2021 Nov 24).","journal-title":"Br J Dermatol"},{"issue":"7","key":"1005_CR18","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/ced.14715","volume":"46","author":"E Brocco","year":"2021","unstructured":"Brocco E, Laffitte E. Risankizumab for pityriasis rubra pilaris. Clin Exp Dermatol. 2021;46(7):1322\u20134. https:\/\/doi.org\/10.1111\/ced.14715. (Epub 2021 Jun 13).","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1005_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19681","volume":"184","author":"J Ricar","year":"2021","unstructured":"Ricar J, Cetkovska P. Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab. Br J Dermatol. 2021;184(5): e148. https:\/\/doi.org\/10.1111\/bjd.19681. (Epub 2020 Dec 4).","journal-title":"Br J Dermatol"},{"issue":"8","key":"1005_CR20","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/ddg.14504","volume":"19","author":"C Kromer","year":"2021","unstructured":"Kromer C, Sch\u00f6n MP, M\u00f6ssner R. Treatment of pityriasis rubra pilaris with risankizumab in two cases. J Dtsch Dermatol Ges. 2021;19(8):1207\u20139. https:\/\/doi.org\/10.1111\/ddg.14504. (Epub 2021 May 10).","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"1005_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15112","volume":"34","author":"R Balestri","year":"2021","unstructured":"Balestri R, Magnano M, Girardelli CR, Rech G. Is risankizumab effective in the treatment of pityriasis rubra pilaris? Dermatol Ther. 2021;34(6): e15112. https:\/\/doi.org\/10.1111\/dth.15112. (Epub 2021 Aug 31).","journal-title":"Dermatol Ther"},{"issue":"1","key":"1005_CR22","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.18516","volume":"37","author":"AL Fouarge","year":"2023","unstructured":"Fouarge AL, Cuvelier M, Roquet-Gravy C, de Montjoye L, Baeck M. Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23\/p19 antagonist. J Eur Acad Dermatol Venereol. 2023;37(1):e106\u20139. https:\/\/doi.org\/10.1111\/jdv.18516. (Epub 2022 Aug 23).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1005_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjd.20061","volume":"185","author":"B Duarte","year":"2021","unstructured":"Duarte B, Paiva Lopes MJ. Response to: \u201cSuccessful treatment of refractory extensive pityriasis rubra pilaris with risankizumab.\u201d Br J Dermatol. 2021;185(1):235\u20136. https:\/\/doi.org\/10.1111\/bjd.20061. (Epub 2021 Apr 18).","journal-title":"Br J Dermatol"},{"issue":"12","key":"1005_CR24","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamadermatol.2019.2774","volume":"155","author":"AC Pilz","year":"2019","unstructured":"Pilz AC, Seiringer P, Biedermann T, Eyerich K. Treatment of pityriasis rubra pilaris with Guselkumab. JAMA Dermatol. 2019;155(12):1424\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2774.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1005_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14403","volume":"33","author":"H Nagai","year":"2020","unstructured":"Nagai H, Jimbo H, Matsuura S, Tatsuoka S, Shiraki E, Nishigori C. Successful treatment of pityriasis rubra pilaris with guselkumab: serum CCL20 as a potential marker for the disease activity. Dermatol Ther. 2020;33(6): e14403. https:\/\/doi.org\/10.1111\/dth.14403. (Epub 2020 Oct 21).","journal-title":"Dermatol Ther"},{"issue":"10","key":"1005_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6413","volume":"10","author":"M Nishimura","year":"2022","unstructured":"Nishimura M, Kondo M, Habe K, Hayashi A, Yamanaka K. Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris. Clin Case Rep. 2022;10(10): e6413. https:\/\/doi.org\/10.1002\/ccr3.6413.","journal-title":"Clin Case Rep"},{"issue":"4","key":"1005_CR27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ajd.13925","volume":"63","author":"JP Pham","year":"2022","unstructured":"Pham JP, Allen N, Smith A. Efficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: a case series. Australas J Dermatol. 2022;63(4):522\u20134. https:\/\/doi.org\/10.1111\/ajd.13925. (Epub 2022 Sep 21).","journal-title":"Australas J Dermatol"},{"issue":"8","key":"1005_CR28","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/ced.14790","volume":"46","author":"G Licata","year":"2021","unstructured":"Licata G, Gambardella A, Calabrese G, Pagliuca F, Alfano R, Argenziano G. Refractory Type I pityriasis rubra pilaris treated with tildrakizumab. Clin Exp Dermatol. 2021;46(8):1594\u20135. https:\/\/doi.org\/10.1111\/ced.14790. (Epub 2021 Jul 14).","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1005_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/ajd.13753","volume":"63","author":"SS Zagarella","year":"2022","unstructured":"Zagarella SS, Jiang KW. Successful treatment of pityriasis rubra pilaris with tildrakizumab. Australas J Dermatol. 2022;63(1):120\u20131. https:\/\/doi.org\/10.1111\/ajd.13753. (Epub 2021 Dec 2).","journal-title":"Australas J Dermatol"},{"issue":"3","key":"1005_CR30","first-page":"337","volume":"6","author":"M G\u00f3mez","year":"2007","unstructured":"G\u00f3mez M, Ruelas ME, Welsh O, Arcaute HD, Ocampo-Candiani J. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. J Drugs Dermatol. 2007;6(3):337\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"5 Suppl","key":"1005_CR31","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/j.jaad.2008.06.016","volume":"59","author":"V Cox","year":"2008","unstructured":"Cox V, Lesesky EB, Garcia BD, O\u2019Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol. 2008;59(5 Suppl):S113\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2008.06.016.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1005_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamadermatol.2013.4773","volume":"150","author":"AB Eastham","year":"2014","unstructured":"Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014;150(1):92\u20134. https:\/\/doi.org\/10.1001\/jamadermatol.2013.4773.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"1005_CR33","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/1346-8138.13038","volume":"42","author":"BR Kim","year":"2015","unstructured":"Kim BR, Chae JB, Park JT, Byun SY, Youn SW. Clinical remission of pityriasis rubra pilaris with adalimumab in an adolescent patient. J Dermatol. 2015;42(11):1122\u20133. https:\/\/doi.org\/10.1111\/1346-8138.13038. (Epub 2015 Jul 27).","journal-title":"J Dermatol"},{"key":"1005_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12559","author":"NJ Maloney","year":"2017","unstructured":"Maloney NJ, Hisaw LD, Worswick S. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: a retrospective investigation. Dermatol Ther. 2017. https:\/\/doi.org\/10.1111\/dth.12559. (Epub 2017 Oct 15).","journal-title":"Dermatol Ther."},{"issue":"2","key":"1005_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jdcr.2017.09.010","volume":"4","author":"L Bonomo","year":"2018","unstructured":"Bonomo L, Raja A, Tan K, Guttman-Yassky E. Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl. JAAD Case Rep. 2018;4(2):206\u201310. https:\/\/doi.org\/10.1016\/j.jdcr.2017.09.010.","journal-title":"JAAD Case Rep"},{"key":"1005_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12577","author":"V Lora","year":"2018","unstructured":"Lora V, De Felice C, Cota C, Graceffa D, Morrone A, Bonifati C. A case of juvenile pityriasis rubra pilaris type III successfully treated with etanercept. Dermatol Ther. 2018. https:\/\/doi.org\/10.1111\/dth.12577. (Epub 2017 Nov 28).","journal-title":"Dermatol Ther."},{"issue":"3","key":"1005_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13431","volume":"33","author":"Z Zhong","year":"2020","unstructured":"Zhong Z, Li J, Xue R, Liang Y, Chen Y. Refractory classic juvenile pityriasis rubra pilaris successfully treated with a combination of etanercept and methotrexate. Dermatol Ther. 2020;33(3): e13431. https:\/\/doi.org\/10.1111\/dth.13431. (Epub 2020 Apr 28).","journal-title":"Dermatol Ther"},{"issue":"6","key":"1005_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14097","volume":"33","author":"JY Liang","year":"2020","unstructured":"Liang JY, Ye RX, Tian X, Zhang SQ, Zhang XB. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: a case report and literature review. Dermatol Ther. 2020;33(6): e14097. https:\/\/doi.org\/10.1111\/dth.14097. (Epub 2020 Sep 4).","journal-title":"Dermatol Ther"},{"issue":"4","key":"1005_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/pde.14994","volume":"39","author":"K Medek","year":"2022","unstructured":"Medek K, Selhofer S, Buchner M, Mrowietz U, Laimer M. Successful treatment of a child\u2019s pityriasis rubra pilaris (PRP) with ustekinumab and acitretin. Pediatr Dermatol. 2022;39(4):659\u201361. https:\/\/doi.org\/10.1111\/pde.14994. (Epub 2022 Jul 20).","journal-title":"Pediatr Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01005-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T11:08:26Z","timestamp":1695899306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01005-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01005-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}